Paper Details

  1. Home
  2. Paper Details

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.

Author: AlexopoulosDimitrios, DamelouAnastasia, DavlourosPeriklis, GkizasVassilios, HahalisGeorge, KassimisGeorge, KoutsogiannisNikolaos, MakrisGeorge, TheodoropoulosKonstantinos C, TsigkasGrigorios, XanthopoulouIoanna

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Ticagrelor and prasugrel, both strong platelet inhibitors, exhibited an initial delay in the onset of their antiplatelet action in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Ticagrelor did not appear superior to prasugrel in reducing platelet reactivity during the first 24 hours.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Ticagrelor and prasugrel provide stronger platelet inhibition compared with clopidogrel. Direct pharmacodynamic comparison between them has not yet been reported in ST-segment-elevation myocardial infarction patients. METHODS AND RESULTS: In a prospective, single-center, single-blind st...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1161/CIRCINTERVENTIONS.112.972323

データ提供：米国国立医学図書館（NLM）

Ticagrelor vs. Prasugrel: Exploring Antiplatelet Effects in ST-Segment-Elevation Myocardial Infarction

ST-segment-elevation myocardial infarction (STEMI) is a life-threatening condition requiring prompt medical intervention. This study compared the antiplatelet effects of ticagrelor and prasugrel, two potent antiplatelet agents, in patients undergoing primary percutaneous coronary intervention (PCI) for STEMI. The researchers aimed to assess the platelet reactivity of each drug and identify potential differences in their effectiveness.

Assessing Platelet Reactivity: A Crucial Factor in STEMI Treatment

The study found that both ticagrelor and prasugrel exhibited initial delays in their antiplatelet action, but their overall effectiveness in reducing platelet reactivity was comparable. The researchers observed no significant difference in platelet reactivity between the two drugs during the first 24 hours after PCI, suggesting that both agents effectively inhibit platelet aggregation in STEMI patients. However, ticagrelor demonstrated a greater reduction in platelet reactivity at day 5, suggesting a longer-lasting effect.

Optimal Antiplatelet Therapy for STEMI: Navigating the Choices

This research provides valuable information for guiding antiplatelet therapy in STEMI patients. The study highlights the importance of understanding the time-dependent effects of different antiplatelet agents and tailoring treatment based on individual patient needs. While both ticagrelor and prasugrel offer significant benefits in reducing platelet reactivity, the choice of agent should consider factors such as the desired duration of antiplatelet effect and the patient's overall medical history.

Dr. Camel's Conclusion

Imagine a desert landscape where the dunes are constantly shifting. STEMI is like that, a dynamic and unpredictable event. This study helps us understand how different antiplatelet agents, like different desert plants, adapt to this changing landscape. By understanding their strengths and weaknesses, we can choose the most effective therapy to navigate the complexities of STEMI treatment.

Date :
  1. Date Completed 2013-06-03
  2. Date Revised 2023-01-20
Further Info :

Pubmed ID

23169985

DOI: Digital Object Identifier

10.1161/CIRCINTERVENTIONS.112.972323

Related Literature

Article Analysis
・Effects of protriptyline・Effects of prasugrel
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.